Market closedNon-fractional

Coherus BioSciences/CHRS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Ticker

CHRS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Redwood City, United States

Employees

249

CHRS Metrics

BasicAdvanced
$153M
Market cap
-
P/E ratio
-$0.58
EPS
0.60
Beta
-
Dividend rate
$153M
0.6
3.6
2.916
-371.868
-587.903
-3.75%
-16.87%
42.60%
0.452
-1.84
-1.08
-0.884
64.63%
-83.38%
-11.98%
-18.29%

What the Analysts think about CHRS

Analyst Ratings

Majority rating from 10 analysts.
Buy

CHRS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
133.50% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$77M
-15.85%
Net income
$103M
-229.15%
Profit margin
133.50%
-253.47%

CHRS Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 32.34%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.27
-$0.62
-$0.32
-
Expected
-$0.48
-$0.27
-$0.12
-$0.24
-$0.17
Surprise
-21.60%
-1.70%
420.28%
32.34%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Coherus BioSciences stock?

Coherus BioSciences (CHRS) has a market cap of $153M as of July 06, 2024.

What is the P/E ratio for Coherus BioSciences stock?

The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 0 as of July 06, 2024.

Does Coherus BioSciences stock pay dividends?

No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Coherus BioSciences dividend payment date?

Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.

What is the beta indicator for Coherus BioSciences?

Coherus BioSciences (CHRS) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Coherus BioSciences stock

Buy or sell Coherus BioSciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing